In the first of a double dose of wins for US biotech Novavax, the company has been granted full marketing authorisation (MA) by the European Commission in the EU for Nuvaxovid (NVX-CoV2373 ...
The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the vaccine was updated to target the JN.1 variant, an offshoot of Omicron. Nationally, the JN.1 group is ...